drugset / Trial / NCT05296564
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
NaSingle-groupOpen-labelTreatment
Summary
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
Timeline
- Start
- 2022-04-01
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HBI 0201-ESO TCRT | Cell therapy | 1e+09 cells | Other |
| Subject | HBI 0201-ESO TCRT | Cell therapy | 5e+09 cells | Other |
| Subject | HBI 0201-ESO TCRT | Cell therapy | 1e+10 cells | Other |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabin | Unknown | 25 mg/m2 | — |
| Background | aldesleukin | Protein / enzyme biologic | 1.8e+07 iu | Other |